Novelix Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	25.57	0.85	0.1	-0.6	-20.27
Depreciation & Amortization	1.01	0.38	0.38	0.56	0.8
Other Amortization	-	-	-	-	0.22
Loss (Gain) From Sale of Assets	-	-	-	-	4.57
Loss (Gain) From Sale of Investments	-	-	-	-	15
Other Operating Activities	8.15	0.23	-2.97	-5.14	4.6
Change in Accounts Receivable	-125.8	-225.94	3.3	-16.52	22.79
Change in Inventory	-135.89	3.51	-3.74	-2.89	-0.7
Change in Accounts Payable	-	84.12	-0.52	0.53	-11.15
Change in Other Net Operating Assets	3.07	-	-	-	-
Operating Cash Flow	-223.89	-136.85	-3.43	-24.05	15.86
Operating Cash Flow Growth	-	-	-	-	-0.42%
Capital Expenditures	-32.56	-1.06	-	-0.04	-17.98
Sale of Property, Plant & Equipment	-	-	0.18	-	-
Investment in Securities	15	30.21	-1.39	22.84	15.08
Other Investing Activities	0.33	0.16	3.07	-22.04	-4.69
Investing Cash Flow	-17.23	29.3	1.86	0.75	-7.6
Issuance of Common Stock	263.93	30.65	-	-	-
Other Financing Activities	-	82.5	-	-	-
Financing Cash Flow	263.93	113.15	-	-	-
Miscellaneous Cash Flow Adjustments	-	0	0	-	-0
Net Cash Flow	22.8	5.61	-1.57	-23.3	8.26
Free Cash Flow	-256.45	-137.91	-3.43	-24.1	-2.12
Free Cash Flow Margin	-19.38%	-44.87%	-7.58%	-125.49%	-2.38%
Free Cash Flow Per Share	-12.14	-14.69	-0.33	-2.98	-0.26
Levered Free Cash Flow	-287.8	-159.47	4.48	10.27	-12.33
Unlevered Free Cash Flow	-287.8	-159.47	4.48	10.27	-11.97
Change in Working Capital	-258.62	-138.3	-0.96	-18.87	10.94